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DIFFERING TIME DEPENDENT CHANGES IN MORTALITY AND TRANSFORMATION RISK IN MYELODYSPLASTIC SYNDROMES SUBGROUPS
TIME-DEPENDENT CHANGES IN MORTALITY AND TRANSFORMATION RISK IN
MDS
. Previously, the comparison of scores was only provided from the time of diagnosis 7 and the stability of risk over time and the clinical applicability for time points after diagnosis remain unclear.
The aim of this multicenter retrospective study therefore was to assess the relative stability of the newly developed scoring systems over time, to compare the observed time-related changes in prognostic power among these systems and to relate these changes to the time-dependence of hazards. These data can then be applied to MDS populations with different risk for their clinical outcomes when evaluated over time after diagnosis and as they relate to their clinical implications.
Patients and Methods
Patients
This study is based on 7,212 untreated (i.e. they did not receive disease modifying treatment during MDS-phase -disease-specific treatment was allowed after progression . Cause-specific hazard was estimated for time to leukemic transformation, and for consistency the related Kaplan-Meier curves are based on these cause-specific hazards, i.e. they do not account for competing risks of death, as the aim was to describe the change of hazard with time, not the description of the cumulative incidence of transformations 15 . The potential influence of scoring weights on stability was analyzed by the creation of hypothetical time-specific scores as landmark reference scores.
The following specific hypotheses connected to the interpretation of results required particular methods: Most scores are based on Cox-models. In these models, a certain set of potential predictors is selected, and the model estimates optimal weights, to form a prognostic score as a weighted sum of these potential predictors. Since the majority of events occurred early, the estimation was dominated by the initial period after diagnosis.
Our question of interest was to determine whether weights, optimized for later periods would improve prediction in these later periods. Therefore, hypothetical scores were estimated for the landmarks 12 to 48 months.
Since the aim of this project did not imply clinically plausible null hypotheses, formal significance tests were not considered appropriate. All analyses were performed using the open source software R version 3.1.2 16 , including the packages "survival"
17
, and
"bshazard"
14
.
For an additional discussion of methods and models used, see the Supplemental methodological material.
Results
Changes in the subgroup specific hazards over time
Changes of hazard over time are shown by smoothed hazard plots, Figure 1A The enlarged section of the survival curves by IPSS-R ( Figure 1B) shows, for example, that the curve for "very high" risk starts at 1.0 (i.e., 100%) (at two months because stable disease for two months was one of the inclusion criteria for the IPSS-R) and declines to about 0.9 (i.e., ca. 90%) after one month (i.e., after 3 months from diagnosis). That means the initial mortality is 10% per month. The smoothed hazard for "very high" risk roughly indicates 0.1 (i.e. 10%) hazard (roughly interpretable as 10% mortality per month) in the beginning (see top arrow in Figure 1A ). This is consistent with data represented by the Kaplan-Meier-curve.
However, after 30 months the hazard plot ( Figure 1A , middle arrow) shows .05, i.e. a 5% monthly mortality for the very high-risk group. While a Kaplan-Meier-curve shows the estimated proportion of persons still alive at each point in follow up time, the hazard plot shows the estimated proportion dying in a defined interval (here one month), given that a person is still alive at the start of the interval of interest. The fact that the force of mortality in the very high risk group decreases from 10% per month to 5% per month after about 2.5 years is clearly visible in the hazard plot, but not readily seen in the survival curve.
For the entire sample (black dashed line, lower arrow), the hazard plot shows 2% mortality per month after diagnosis, and about 1% after 120 months. It can be seen that the mortality risks of the remaining patients for all risk groups are similar after about 60 months. The graph illustrates that similarity of risks derives mainly from a decline in the higher risk groups (IPSS-R very high and high), whereas the mortality risk in the lower risk groups (IPSS-R low and very low) remains essentially unchanged.
In Figure 2 , the typical Kaplan-Meier plots are shown adjacent to hazard plots to Table 1 ). Compared to evaluation of survival, we observed a weaker decline of prognostic power with respect to time to transformation to AML. Figure 3 demonstrates that the prognostic power of the IPSS-R after about 9 months remains as high as that of the original IPSS at diagnosis for both endpoints. Similarly, the IPSS-RA maintains a comparable power until around 14 months after diagnosis (see gray arrows in Figure 3 ). The IPSS-R performs generally better if the patient sample is restricted to WHO-defined-MDS (excluding oligoblastic AML) (see Table 1 , line "IPSS-R WHO only").
IPSS-R vs IPSS and FAB vs WHO
WPSS
The WPSS variants show high initial prognostic power with loss in power over time, similar to that of other scoring systems. A meaningful comparison with the IPSS-R, necessarily based on WHO classifiable patients only, demonstrates similar initial high prognostic power and attenuation over time.
Inclusion of age in prognostic scoring systems
Inclusion of patient´s age results in higher initial prognostic power and better stability in predicting survival but not for time to AML progression (see comparison of scores with and without age adjustment in Table 1 and Figure 3A ).
Stability of scores in lower vs higher risk patients
Scores applied to lower risk MDS only show generally lower prognostic power ( because of less risk variation), but remain more stable over time (see Table 1 , lines "LR-PSS in LR" and " IPSS in LR"), because they are less affected by the attenuation of subgroup specific hazards ( Figures 4B, 4D ). This is seen for both the LR-PSS -initially derived 
Decline of prognostic power over time in potential prognostic variables
Decline of prognostic power for single potential prognostic variables as measured by Dxy is tabulated in Table 1 . Bone marrow blast percentage is the strongest single predictor. Its predictive loss over time is in line with most other parameters and scores.
Cytogenetic pattern is of high importance at time of diagnosis with steady loss of prognostic power. Beta-2 microglobulin and performance status (only available for a subset of patients) seem to have moderate, but stable influence on survival and increasing influence on time to progression. As a plausibility check of the analysis, conversely, age showed growing negative impact on survival, although not on time to AML progression.
Improvement by hypothetical time-specific scores
Given that most potential prognostic variables exhibit loss of prognostic power over time,
we investigated the effect of assigning different weights to score-constituting Table 1 . These landmark reference scores do not show higher prognostic power for target times, but rather attenuation of prognostic power.
Consequences for dichotomization into lower risk versus higher risk MDS
Based on prognostic power and on the differing declines of hazards in IPSS-R categories, the optimal dichotomization into just two risk categories -as usually employed in clinical practice -lower risk versus higher risk MDS patients -is the division obtained by using an IPSS-R score of The lower risk group proposed now includes a smaller proportion of cases than the original IPSS lower risk group, consequently assigning more patients to the higher risk group.
Discussion
MDS have been described as a spectrum of dynamic disorders, where clonal evolution identified at a cytogenetic and molecular level may trigger progression [18] [19] .
On the other hand, time of disease progression may be heterogeneous When using prognostic risk scoring systems in clinical daily practice, we assume implicitly that the risk within a specific risk category remains constant over the entire course of the disease. However, the present study showed that all the scoring systems we evaluated for MDS risk categories discriminated better at time of diagnosis compared to later time points (Figure 3 , Table 1 ). In detail, our data demonstrated significant timedependent changes in the risk for both overall survival and leukemic transformation during elapsing time, which differed for specified patient populations (Figure 2 ). For higher-risk patients, the mortality risk declined more sharply over time, approaching that observed in lower-risk MDS, whereas for lower-risk patients the mortality risk remained essentially unchanged during follow-up.
One potential explanation for this finding is, that the risk for AML transformation, which has a greater impact in the high risk subset of patients, decreases more dramatically compared to overall survival (Figure 2 F, H) . In contrast, age-related risk of death, which has a more pronounced effect on mortality in lower-risk patients, increased with time (Table 1) . Risk attenuation is at least partially caused by selective loss of higher-risk patients over time. This loss may be an event such as death or leukemic transformation.
In addition, a selection bias cannot be ruled out: the IWG-PM data set used for developing the IPSS-R only includes untreated patients and it is most likely that a greater proportion of higher-risk compared to lower-risk patients is actively treated with passing time from diagnosis, and thus selectively excluded from this study. As changes in risk over time may stem from disease-specific and also from patient-related factors such as comorbidities, loss of prognostic power over time may be not due to a poor quality of the scoring systems analyzed but to inherent survival dynamics of the MDS patient population.
Theoretically, loss of prognostic power could also result from suboptimal weights of score components. We ruled out this possibility by providing hypothetical scores, optimized for later time intervals comparable to landmark analyses, and observed that these hypothetical scores lost prognostic power in a comparable fashion (Supplemental Table 1 ). In addition, as single parameters decline to a similar extent, better weighting of these variables at time of diagnosis did not mitigate the decline of prognostic power of scores over time (Table 1) . Data using somatic mutational molecular parameters with potential for prognosis 18,21,22 will be of much interest for future analysis. The potential stability of such mutations over time requires further study.
As loss of stability in prognostic scores exists, the question of the best approach for patient re-evaluation arises. Conventionally, the time of first bone marrow examination with features defining MDS is accepted as the time of diagnosis 23 . On the assumption that the impact of features changes little, and remembering different stability of hazards in different risk categories, scoring systems such as the IPSS-R may be used for reevaluation after diagnosis, at time points where still clinically meaningful conclusions can be drawn from risk score categories. Re-evaluation could be done at specific intervals established according to clinical needs (e.g., every six months for higher risk patients and at longer intervals for lower risk patients).
Our data on the differential development of risks for the single score subgroups suggest also for the first time a reasonable division into lower risk and higher risk MDS into two groups based on the IPSS-R, a fact that may be valuable for design of clinical trials and for patient management. As described, lower risk MDS have virtually constant risk for both endpoints, whereas in higher-risk cases risk diminishes substantially over time. If the aim is optimal prognostic separation of lower risk versus higher risk patients, then a dichotomization based on 3.5 scoring points of the IPSS-R raw score (i.e. yielded the best results. This also best represents the different changes in risk categories over time ( Figure 5 , Table 1 ). In particular, all patients scoring >3.5 points fit well into the higher risk group. The proportion of lower risk patients using this dichotomization is smaller compared to the lower risk group of the original IPSS, which was heterogenous and contained patients with higher risk.
Our results serve to underscore the ongoing processes occurring during the course of the disease and should help guide clinical decisions in MDS. One interpretation relates to a new perception of higher and lower risk MDS where lower risk patient subgroups may be better described as a group of patients with "constant lower risk" (risk remaining the same over time) whereas the term "initially higher risk" MDS (but with decreasing risk over time) fits higher risk subgroups better. Although our data are derived from "untreated" MDS patients, this is a representative patient cohort since the majority of MDS patients are still provided with supportive care without disease-modifying treatment 24, 25 . Future analysis of patients receiving treatment and comparison with the data presented herein are planned and may indicate the impact of therapy.
The following clinical recommendations can be derived from our data: If a patient is initially categorized as high risk, options for disease-modifying treatment should be considered immediately, and if deemed appropriate, a decision for treatment should be made as early as possible. If in contrast, due to comorbidities, decreased performance status, clinical stability or other reasons a high risk patient does not receive diseasemodifying treatment at time of diagnosis, but remains in stable condition for a prolonged period, re-evaluation for a specific treatment should be re-considered at that time. For lower risk patients it should be noted that risk remains relatively constant over time, therefore surveillance and ongoing re-evaluation should be maintained long term.
In conclusion, our data describe the change of risk within prognostic score categories over time in MDS and their effects on the construction and interpretation of prognostic scoring systems. Clinicians should be aware of these facts when assessing patients after time intervals and when making treatment decisions. This study clearly demonstrates that a cut-off point of 3.5 in the IPSS-R scoring system is the best for segregating MDS patients into two risk groups -lower risk and higher risk -for therapeutic purposes, although a loss of prognostic power compared to the use of raw score data or the five IPSS-R category approach should be noted. Since the statistical tools used in our analysis may be applied to other prognostic scoring systems, it will be of interest to determine whether similar changes of risk over time are observed in other disease entities.
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